These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24779206)

  • 1. Legal instruments supporting the development of orphan medicinal products in the European Union.
    Miaskowska-Daszkiewicz K
    Acta Pol Pharm; 2014; 71(1):181-7. PubMed ID: 24779206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Medicines Agency support mechanisms fostering orphan drug development.
    Butlen-Ducuing F; Rivière F; Aarum S; Llinares-Garcia J
    Drug News Perspect; 2010; 23(1):71-81. PubMed ID: 20155221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory exclusivities for medicinal products for human use in the EU.
    Schoonderbeek C; Jong B
    Pharm Pat Anal; 2016; 5(1):5-8. PubMed ID: 26674744
    [No Abstract]   [Full Text] [Related]  

  • 9. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
    Dear JW; Lilitkarntakul P; Webb DJ
    Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European regulation on orphan medicinal products: 10 years of experience and future perspectives.
    ; Westermark K; Holm BB; Söderholm M; Llinares-Garcia J; Rivière F; Aarum S; Butlen-Ducuing F; Tsigkos S; Wilk-Kachlicka A; N'Diamoi C; Borvendég J; Lyons D; Sepodes B; Bloechl-Daum B; Lhoir A; Todorova M; Kkolos I; Kubáčková K; Bosch-Traberg H; Tillmann V; Saano V; Héron E; Elbers R; Siouti M; Eggenhofer J; Salmon P; Clementi M; Krieviņš D; Matulevičiene A; Metz H; Vincenti AC; Voordouw A; Dembowska-Bagińska B; Nunes AC; Saleh FM; Foltánová T; Možina M; Torrent i Farnell J; Beerman B; Mariz S; Evers MP; Greene L; Thorsteinsson S; Gramstad L; Mavris M; Bignami F; Lorence A; Belorgey C
    Nat Rev Drug Discov; 2011 May; 10(5):341-9. PubMed ID: 21532564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing rarity in the context of orphan medicinal product designation in the European Union.
    Tsigkos S; Hofer MP; Sheean ME; Mariz S; Larsson K; Naumann-Winter F; Fregonese L; Sepodes B
    Drug Discov Today; 2018 Mar; 23(3):681-686. PubMed ID: 28647377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do we need authorized orphan drugs when compounded medications are available?
    Dooms M; Pincé H; Simoens S
    J Clin Pharm Ther; 2013 Feb; 38(1):1-2. PubMed ID: 22973866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drug development across Europe: bottlenecks and opportunities.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Drug Discov Today; 2008 Aug; 13(15-16):670-6. PubMed ID: 18583178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.